Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

David B. Price (Corresponding Author), Sinthia Bosnic-Anticevich, Ian D. Pavord, Nicolas Roche, David M. G. Halpin, Leif Bjermer, Omar S. Usmani, Guy Brusselle, Simon Wan Yau Ming, Sarang Rastogi

Research output: Contribution to journalArticle

1 Citation (Scopus)
1 Downloads (Pure)

Abstract

Background Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. Methods This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18–80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 109 cells/L; non-high: < 0.300 × 109 cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. Results In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). Conclusion The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations.
Original languageEnglish
Article number41
Number of pages18
JournalClinical and Translational Allergy
Volume9
Issue number1
DOIs
Publication statusPublished - 21 Aug 2019

Fingerprint

Eosinophils
Nitric Oxide
Asthma
Biomarkers
Reading
Research
Observational Studies
Prescriptions
Primary Health Care
Patient Care
Adrenal Cortex Hormones
Databases
Confidence Intervals

Keywords

  • Asthma
  • blood eosinophils
  • exhaled airway markers
  • nitric oxide
  • Exhaled airway markers
  • Blood eosinophils
  • Nitric oxide
  • MULTICENTER
  • MEPOLIZUMAB
  • GUIDELINES
  • ADULTS
  • INHALED CORTICOSTEROIDS
  • PERSISTENT ASTHMA
  • CARE

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Immunology

Cite this

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. / Price, David B. (Corresponding Author); Bosnic-Anticevich, Sinthia; Pavord, Ian D.; Roche, Nicolas; Halpin, David M. G.; Bjermer, Leif; Usmani, Omar S.; Brusselle, Guy; Ming, Simon Wan Yau; Rastogi, Sarang.

In: Clinical and Translational Allergy, Vol. 9, No. 1, 41, 21.08.2019.

Research output: Contribution to journalArticle

Price, DB, Bosnic-Anticevich, S, Pavord, ID, Roche, N, Halpin, DMG, Bjermer, L, Usmani, OS, Brusselle, G, Ming, SWY & Rastogi, S 2019, 'Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations', Clinical and Translational Allergy, vol. 9, no. 1, 41. https://doi.org/10.1186/s13601-019-0282-7
Price, David B. ; Bosnic-Anticevich, Sinthia ; Pavord, Ian D. ; Roche, Nicolas ; Halpin, David M. G. ; Bjermer, Leif ; Usmani, Omar S. ; Brusselle, Guy ; Ming, Simon Wan Yau ; Rastogi, Sarang. / Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. In: Clinical and Translational Allergy. 2019 ; Vol. 9, No. 1.
@article{dd9de81a76384851aebff274f9dc9ca0,
title = "Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations",
abstract = "Background Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. Methods This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18–80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 109 cells/L; non-high: < 0.300 × 109 cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. Results In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95{\%} confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). Conclusion The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations.",
keywords = "Asthma, blood eosinophils, exhaled airway markers, nitric oxide, Exhaled airway markers, Blood eosinophils, Nitric oxide, MULTICENTER, MEPOLIZUMAB, GUIDELINES, ADULTS, INHALED CORTICOSTEROIDS, PERSISTENT ASTHMA, CARE",
author = "Price, {David B.} and Sinthia Bosnic-Anticevich and Pavord, {Ian D.} and Nicolas Roche and Halpin, {David M. G.} and Leif Bjermer and Usmani, {Omar S.} and Guy Brusselle and Ming, {Simon Wan Yau} and Sarang Rastogi",
note = "Acknowledgements The authors thank Gokul Gopalan and Sadia Halim for their contributions to the development of a poster based on the findings of this study, which was presented at the British Thoracic Society (BTS) Winter Meeting, 6–8 December 2017, London, United Kingdom. Editorial support was provided by Michelle Rebello, PhD, of Cactus Communications (Mumbai, India) and Michael A. Nissen, ELS, of AstraZeneca (Gaithersburg, MD, USA) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This support was fully funded by AstraZeneca. Funding This study was funded by AstraZeneca. Availability of data and materials Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",
year = "2019",
month = "8",
day = "21",
doi = "10.1186/s13601-019-0282-7",
language = "English",
volume = "9",
journal = "Clinical and Translational Allergy",
issn = "2045-7022",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

AU - Price, David B.

AU - Bosnic-Anticevich, Sinthia

AU - Pavord, Ian D.

AU - Roche, Nicolas

AU - Halpin, David M. G.

AU - Bjermer, Leif

AU - Usmani, Omar S.

AU - Brusselle, Guy

AU - Ming, Simon Wan Yau

AU - Rastogi, Sarang

N1 - Acknowledgements The authors thank Gokul Gopalan and Sadia Halim for their contributions to the development of a poster based on the findings of this study, which was presented at the British Thoracic Society (BTS) Winter Meeting, 6–8 December 2017, London, United Kingdom. Editorial support was provided by Michelle Rebello, PhD, of Cactus Communications (Mumbai, India) and Michael A. Nissen, ELS, of AstraZeneca (Gaithersburg, MD, USA) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This support was fully funded by AstraZeneca. Funding This study was funded by AstraZeneca. Availability of data and materials Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

PY - 2019/8/21

Y1 - 2019/8/21

N2 - Background Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. Methods This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18–80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 109 cells/L; non-high: < 0.300 × 109 cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. Results In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). Conclusion The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations.

AB - Background Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations. Methods This observational study included data from the Optimum Patient Care Research Database. Asthma patients (18–80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 109 cells/L; non-high: < 0.300 × 109 cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; non-high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised. Results In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]). Conclusion The combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations.

KW - Asthma

KW - blood eosinophils

KW - exhaled airway markers

KW - nitric oxide

KW - Exhaled airway markers

KW - Blood eosinophils

KW - Nitric oxide

KW - MULTICENTER

KW - MEPOLIZUMAB

KW - GUIDELINES

KW - ADULTS

KW - INHALED CORTICOSTEROIDS

KW - PERSISTENT ASTHMA

KW - CARE

UR - http://www.scopus.com/inward/record.url?scp=85070956142&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/association-elevated-fractional-exhaled-nitric-oxide-concentration-blood-eosinophil-count-severe-ast

U2 - 10.1186/s13601-019-0282-7

DO - 10.1186/s13601-019-0282-7

M3 - Article

VL - 9

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

IS - 1

M1 - 41

ER -